Recent blog posts
The Phase 3 LUNA 3 trial of Rilzabrutinib successfully achieved its main goal in treating immune thrombocytopenia
Latest Hotspot
3 min read
The Phase 3 LUNA 3 trial of Rilzabrutinib successfully achieved its main goal in treating immune thrombocytopenia
25 April 2024
The recent phase 3 LUNA 3 trial demonstrated that 400 mg of rilzabrutinib taken orally twice daily effectively achieved the primary goal of sustaining platelet response in adults with persistent or chronic immune thrombocytopenia.
Read →
FDA Approves ImmunityBio’s ANKTIVA® for BCG-Resistant Bladder Cancer
Latest Hotspot
3 min read
FDA Approves ImmunityBio’s ANKTIVA® for BCG-Resistant Bladder Cancer
25 April 2024
ImmunityBio Receives FDA Nod for ANKTIVA®, a Novel IL-15 Receptor Stimulator, for Treating BCG-Resistant Non-Muscle Invasive Bladder Cancer.
Read →
Neurogene to Present Early Results on NGN-401 Gene Therapy for Rett Syndrome at ASGCT Conference
Latest Hotspot
3 min read
Neurogene to Present Early Results on NGN-401 Gene Therapy for Rett Syndrome at ASGCT Conference
25 April 2024
Neurogene Set to Reveal NGN-401 Gene Therapy Safety Results from Early Stage Trial for Rett Syndrome during ASGCT Conference.
Read →
Adicet Bio Showcases Preclinical Readiness of ADI-270 for IND at 27th ASGCT Meeting
Latest Hotspot
3 min read
Adicet Bio Showcases Preclinical Readiness of ADI-270 for IND at 27th ASGCT Meeting
25 April 2024
Adicet Bio presents preclinical findings indicating IND preparedness for ADI-270 during a talk at the 27th Annual ASGCT Meeting.
Read →
ASLAN Pharmaceuticals Announces Positive Early Results from Phase 2 Eblasakimab Trial in Atopic Dermatitis Patients Previously on Dupilumab
Latest Hotspot
3 min read
ASLAN Pharmaceuticals Announces Positive Early Results from Phase 2 Eblasakimab Trial in Atopic Dermatitis Patients Previously on Dupilumab
24 April 2024
ASLAN Pharmaceuticals Reports Encouraging Preliminary Outcomes from a Phase 2 Trial of Eblasakimab in Patients with Atopic Dermatitis Previously Treated with Dupilumab.
Read →
AGA China Phase II Study GT20029 Successfully Meets Its Primary Goal
Latest Hotspot
3 min read
AGA China Phase II Study GT20029 Successfully Meets Its Primary Goal
24 April 2024
Kintor Pharmaceutical Limited announced that its innovative proteolysis targeting chimera compound, GT20029, targeting the androgen receptor (AR), has achieved the primary endpoint in a phase II trial in China.
Read →
EU Commission Approves BIMZELX® for Hidradenitis Suppurativa, First Biologic Targeting IL-17A and IL-17F
Latest Hotspot
3 min read
EU Commission Approves BIMZELX® for Hidradenitis Suppurativa, First Biologic Targeting IL-17A and IL-17F
24 April 2024
The European Commission has granted UCB approval for BIMZELX®(bimekizumab), marking it as the initial biologic targeting both IL-17A and IL-17F for treating moderate to severe hidradenitis suppurativa.
Read →
FDA Approves Takeda's ENTYVIO® for Crohn’s Disease Treatment
Latest Hotspot
3 min read
FDA Approves Takeda's ENTYVIO® for Crohn’s Disease Treatment
24 April 2024
U.S. FDA Sanctions Takeda’s ENTYVIO® (vedolizumab) for Subcutaneous Use in Managing Moderate to Severe Crohn’s Disease.
Read →
Chugai In-Licenses RNAi Therapeutic Zilebesiran for Hypertension with High Cardiovascular Risk
Latest Hotspot
3 min read
Chugai In-Licenses RNAi Therapeutic Zilebesiran for Hypertension with High Cardiovascular Risk
24 April 2024
Chugai Secures Licensing Deal with Roche for Hypertension Drug Zilebesiran in Japan.
Read →
Cerevel Therapeutics Reveals Encouraging Initial Outcomes from Phase 3 Supplementary Study of Tavapadon in Parkinson’s Disease Patients
Latest Hotspot
3 min read
Cerevel Therapeutics Reveals Encouraging Initial Outcomes from Phase 3 Supplementary Study of Tavapadon in Parkinson’s Disease Patients
23 April 2024
Cerevel Therapeutics Reveals Encouraging Initial Outcomes from Phase 3 Supplementary Study of Tavapadon in Parkinson’s Disease Patients.
Read →
MICA/B Antibody DM919 Enters Phase 1 Trial for Advanced Solid Tumors by D2M Biotherapeutics
Latest Hotspot
3 min read
MICA/B Antibody DM919 Enters Phase 1 Trial for Advanced Solid Tumors by D2M Biotherapeutics
23 April 2024
D2M Biotherapeutics has initiated a Phase 1 trial by administering the first dose of DM919, an innovative MICA/B antibody, aimed at treating individuals with advanced solid tumors.
Read →
Pathios Gains $25M for Immunotherapy Trials in Series B Funding
Latest Hotspot
3 min read
Pathios Gains $25M for Immunotherapy Trials in Series B Funding
23 April 2024
Pathios Therapeutics Secures $25M in Initial Series B Funding Round to Propel Unique Immunotherapy Strategy into Clinical Trials.
Read →